VIZAMYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vizamyl, and what generic alternatives are available?
Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-four patent family members in twenty-five countries.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Vizamyl
Vizamyl was eligible for patent challenges on October 25, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VIZAMYL
| International Patents: | 84 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 6 |
| Patent Applications: | 126 |
| Drug Prices: | Drug price information for VIZAMYL |
| What excipients (inactive ingredients) are in VIZAMYL? | VIZAMYL excipients list |
| DailyMed Link: | VIZAMYL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIZAMYL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1 |
| University of Utah | Phase 2 |
| University Hospital, Toulouse | Early Phase 1 |
Pharmacology for VIZAMYL
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for VIZAMYL
VIZAMYL is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIZAMYL is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIZAMYL
Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: DIAGNOSTIC RADIOIMAGING
Benzothiazole derivative compounds, compositions and uses
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Radiopharmaceutical composition
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIZAMYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIZAMYL
When does loss-of-exclusivity occur for VIZAMYL?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08292201
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0815129
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 94084
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1790387
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 82988
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 82988
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 46710
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 500007
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 3316
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 67708
Estimated Expiration: ⤷ Try a Trial
Patent: 10536931
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 10002196
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 3616
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 15006
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 82988
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 82988
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 75267
Estimated Expiration: ⤷ Try a Trial
Patent: 10101935
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1000718
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1571572
Estimated Expiration: ⤷ Try a Trial
Patent: 100055440
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 64715
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIZAMYL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 201000718 | Radiopharmaceutical composition | ⤷ Try a Trial |
| Hungary | 1500560 | Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease | ⤷ Try a Trial |
| China | 1285582 | ⤷ Try a Trial | |
| Canada | 2438032 | DERIVES DE BENZOTHIAZOLE ET COMPOSITIONS ET UTILISATIONS CONNEXES (BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES) | ⤷ Try a Trial |
| Brazil | PI0113470 | composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal | ⤷ Try a Trial |
| European Patent Office | 2182988 | COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIZAMYL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1611115 | C 2015 004 | Romania | ⤷ Try a Trial | PRODUCT NAME: FLUTEMETAMOL (18 F) SAU O SARE, HIDRAT SAU SOLVAT ALACESTUIA ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/14/941; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/941; DATE OF FIRST AUTHORISATION IN EEA: 20140822 |
| 2182988 | 122015000017 | Germany | ⤷ Try a Trial | PRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| 1611115 | 2015/004 | Ireland | ⤷ Try a Trial | PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| 2182988 | CA 2015 00008 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RADIOAKTIVE ISOTOPER AF FLUTEMETAMOL, SAERLIGT FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822 |
| 1611115 | C20150004 00139 | Estonia | ⤷ Try a Trial | PRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014 |
| 1611115 | 193 5003-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
